The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid CancerJ. Taprogge, Glenn Flux, Carla Abreu et al.|Journal of Nuclear Medicine|2023Cited by 19
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJonathan Wadsley, Sarah Brown, Kate Garcez et al.|Thyroid|2023Cited by 19
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah Buckley, Naveen Vasudev, Fiona Collinson et al.|BMC Cancer|2019Cited by 17
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)Naveen Vasudev, Thomas Powles, Gemma Ainsworth et al.|Journal of Clinical Oncology|2023Cited by 14
Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal OsteopeniaAfroze Abbas, Paul M. Stewart, Marian Schini et al.|The Journal of Clinical Endocrinology & Metabolism|2022Cited by 11